ESMO
GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Bevacizumab JO25567

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

PFS

ADJUSTMENTS

Quality of life

No improvement in QoL

Serious and disabling adverse effects

Other adjustments

Mature data shows no OS advantage and no improved QoL

Bevacizumab JO25567

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

2

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations
Experimental Arm: Bevacizumab + Erlotinib
Control Arm: Erlotinib